SI-BONE (SIBN) Set to Announce Earnings on Monday

SI-BONE (NASDAQ:SIBN - Get Free Report) will be issuing its quarterly earnings data after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.02. The business had revenue of $38.86 million during the quarter, compared to the consensus estimate of $38.60 million. SI-BONE had a negative return on equity of 28.22% and a negative net margin of 31.20%. On average, analysts expect SI-BONE to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SI-BONE Stock Up 0.5 %

Shares of NASDAQ:SIBN traded up $0.08 during mid-day trading on Monday, reaching $14.65. 358,473 shares of the stock were exchanged, compared to its average volume of 431,931. The company has a quick ratio of 8.15, a current ratio of 9.01 and a debt-to-equity ratio of 0.21. The company has a market cap of $601.53 million, a P/E ratio of -12.85 and a beta of 1.20. SI-BONE has a one year low of $14.12 and a one year high of $29.51. The stock's 50 day simple moving average is $16.47 and its 200-day simple moving average is $18.12.

Insider Activity

In related news, insider Anthony J. Recupero sold 3,330 shares of SI-BONE stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $16.82, for a total transaction of $56,010.60. Following the completion of the sale, the insider now directly owns 255,760 shares of the company's stock, valued at approximately $4,301,883.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, insider Anthony J. Recupero sold 3,330 shares of the business's stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $16.82, for a total transaction of $56,010.60. Following the completion of the transaction, the insider now owns 255,760 shares of the company's stock, valued at approximately $4,301,883.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mika Nishimura sold 2,500 shares of the business's stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $16.22, for a total value of $40,550.00. Following the transaction, the director now directly owns 19,350 shares of the company's stock, valued at approximately $313,857. The disclosure for this sale can be found here. Insiders sold a total of 11,562 shares of company stock valued at $185,285 over the last three months. Insiders own 5.40% of the company's stock.

Analyst Upgrades and Downgrades

SIBN has been the subject of a number of research reports. Piper Sandler initiated coverage on SI-BONE in a report on Thursday, March 28th. They set an "overweight" rating and a $25.00 price objective for the company. Needham & Company LLC restated a "buy" rating and issued a $27.00 price target on shares of SI-BONE in a research note on Wednesday, April 3rd. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price target on shares of SI-BONE in a research note on Tuesday, February 27th. Morgan Stanley raised their price target on SI-BONE from $25.00 to $26.00 and gave the company an "overweight" rating in a research note on Tuesday, February 27th. Finally, Truist Financial restated a "buy" rating and issued a $24.00 price target (down from $26.00) on shares of SI-BONE in a research note on Tuesday, February 27th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $26.67.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.